Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Down 14.8% - Time to Sell?

Key Points

• Ono Pharmaceutical's shares fell 14.8% on Wednesday, trading at a low of $10.27, with volume dropping to approximately 1,000 shares, significantly below the average of 6,838 shares.
• The company's recent earnings report showed an EPS of $0.26, missing analysts' expectations by $0.08, though revenue of $886.27 million surpassed estimates of $827.29 million.
• Ono Pharmaceutical has a market cap of $4.82 billion and a debt-to-equity ratio of 0.13, indicating a relatively low level of debt compared to equity.

Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report) were down 14.8% during trading on Wednesday . The company traded as low as $10.27 and last traded at $10.27. Approximately 1,000 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 6,838 shares. The stock had previously closed at $12.05.

Ono Pharmaceutical Price Performance

The company's 50-day moving average is $11.46 and its two-hundred day moving average is $11.04. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.99 and a quick ratio of 2.44. The firm has a market cap of $4.82 billion, a P/E ratio of 16.56 and a beta of 0.19.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.34 by ($0.08). Ono Pharmaceutical had a net margin of 8.75% and a return on equity of 5.47%. The firm had revenue of $886.27 million during the quarter, compared to the consensus estimate of $827.29 million.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia.